|Day Low/High||73.36 / 74.55|
|52 Wk Low/High||60.89 / 85.97|
Stocks in the health care sector seem to have no underpinnings whatsoever.
A short "Takeaways" today as I have to prepare for some morning meetings. Down, up, down -- in a relatively volatile session. I am comfortable with yesterday's bearish moves. I sold more (short) today on the surprising (at least to me!) ramp...
Don't get excited by Take Under Monday. The technical picture is mixed. A stronger U.S. dollar presents multi-national vulnerability. This is consistent with Goldman Sachs lowering their three-year S&P 500 profits picture. Peak Sports Viewer...
It's nice to see some positive analyst commentary on Gilead Sciences this week. The biotech stalwart has had Buy ratings reiterated at three analyst firms in recent days. Also, earlier this week Gilead posted very positive results from trials around...
The media is not the message. With a little help from Johnny Mercer, did you know he founded Capitol Records? This is serious folks -- I see less of a reason to have an outsized long portfolio than at any time since Winter 2007. The market outlook...
On days like this, the money just keeps sloshing around.
It was a nostalgic morning. A 20th anniversary. My first TST column in 1997. There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Apart from the Fed, there are other factors that make investors nervous.
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
The once-mighty biotech has fallen, but entry opportunities will surface.
It's been a nasty decline, but if we rally, these three have best charts.
If and when interest rates go up, this basket of stocks should continue to do well.
U.S. stocks rose Tuesday, as oil prices added one percent on hopes of a production freeze among the world's biggest oil producers.
Gilead may be a value trap as investors grow frustrated after two years of stagnant growth.
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.
Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer of plans to buy Medivation for $14 billion. Gilead Sciences is getting some flak for not pursuing Medivation more heavily, but I ...
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.